Optimization protocol for amyloid‐β peptides detection in human cerebrospinal fluid using SELDI TOF MS

Purpose: The aim of the present work was to set up an optimized protocol for human cerebrospinal fluid amyloid‐β (Aβ) profiling.

[1]  J. Trojanowski,et al.  Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques. , 1996, The American journal of pathology.

[2]  Henrik Zetterberg,et al.  Determination of β-Amyloid Peptide Signatures in Cerebrospinal Fluid Using Immunoprecipitation-Mass Spectrometry , 2006 .

[3]  Anders Wallin,et al.  An Alzheimer's disease-specific β-amyloid fragment signature in cerebrospinal fluid , 2006, Neuroscience Letters.

[4]  J. Kornhuber,et al.  Highly conserved and disease‐specific patterns of carboxyterminally truncated Aβ peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer's disease and in patients with chronic neuroinflammation , 2002, Journal of neurochemistry.

[5]  R. Nitsch,et al.  Cerebrospinal Fluid Profile of Amyloid β Peptides in Patients with Alzheimer’s Disease Determined by Protein Biochip Technology , 2004, Neurodegenerative Diseases.

[6]  D. Selkoe,et al.  Amyloid β-peptide is produced by cultured cells during normal metabolism , 1992, Nature.

[7]  D. Teplow,et al.  Amyloid beta-peptide is produced by cultured cells during normal metabolism. , 1992, Nature.

[8]  Henrik Zetterberg,et al.  Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. , 2007, Journal of proteome research.

[9]  A. Goate,et al.  Mutations in APP have independent effects on Abeta and CTFgamma generation. , 2004, Neurobiology of disease.

[10]  T. Iwatsubo,et al.  Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43) , 1994, Neuron.

[11]  M. Tabaton,et al.  Heterogeneity of water‐soluble amyloid β‐peptide in Alzheimer's disease and Down's syndrome brains , 1997, FEBS letters.

[12]  K. Blennow,et al.  Amyloid β1–40 Quantification in CSF: Comparison between Chromatographic and Immunochemical Methods , 2007, Dementia and Geriatric Cognitive Disorders.

[13]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[14]  Anders Wallin,et al.  Amino-Truncated β-Amyloid42 Peptides in Cerebrospinal Fluid and Prediction of Progression of Mild Cognitive Impairment , 2005 .

[15]  A. Goate,et al.  Mutations in APP have independent effects on Aβ and CTFγ generation , 2004, Neurobiology of Disease.

[16]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[17]  P. Lewczuk,et al.  The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide. , 2003, Rapid communications in mass spectrometry : RCM.

[18]  Anders Wallin,et al.  Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment. , 2005, Clinical chemistry.

[19]  S. Sisodia.  Beta-amyloid precursor protein cleavage by a membrane-bound protease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[20]  P. Rossini,et al.  Novel T719P AbetaPP mutation unbalances the relative proportion of amyloid-beta peptides. , 2009, Journal of Alzheimer's disease : JAD.

[21]  P. Lansbury,et al.  The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. , 1993, Biochemistry.

[22]  K. Blennow,et al.  O3-01-04 Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry , 2006, Alzheimer's & Dementia.

[23]  J. Trojanowski,et al.  Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease. , 2006, Acta neuropathologica.

[24]  A. Delacourte,et al.  Truncated beta‐amyloid peptide species in pre‐clinical Alzheimer's disease as new targets for the vaccination approach , 2003, Journal of neurochemistry.

[25]  P. Lewczuk,et al.  The amyloid-β (Aβ) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Aβ peptide , 2003 .

[26]  T. Iwatsubo,et al.  Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). , 1994, Neuron.

[27]  G. Damonte,et al.  Association of a presenilin 1 S170F mutation with a novel Alzheimer disease molecular phenotype. , 2007, Archives of neurology.

[28]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.